首页> 外文期刊>Circulation journal >Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure.
【24h】

Comparative effects of carvedilol vs bisoprolol for severe congestive heart failure.

机译:卡维地洛与比索洛尔治疗严重充血性心力衰竭的比较效果。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Although carvedilol and bisoprolol are effective medicines for the treatment of patients with heart failure (HF), only a few reports have compared their effects. This study was designed to compare the effects of them in patients with severe HF. METHODS AND RESULTS: A total of 655 consecutive patients with HF, categorized as New York Heart Association Class 3 or 4, were retrospectively investigated. Of these patients, 217 were administered beta-blockers after admission and were divided into 2 groups (carvedilol, n=110; bisoprolol, n=107). No significant differences were observed in their characteristics between the 2 groups prior to the introduction of the beta-blockers. After 18 months of follow-up, there were no significant differences in the survival and cardiac event-free rates between the 2 groups. In contrast, there were several significant differences in patients with atrial fibrillation (AF) (carvedilol, n=40; bisoprolol, n=43). The percent changes in heart rate and brain natriuretic peptide level improved significantly in the bisoprolol group than in the carvedilol group. Furthermore, more patients in the bisoprolol group were defibrillated from AF to sinus rhythm than those in the carvedilol group (48% vs 16%; P=0.03). CONCLUSIONS: Our data suggest that the 2 beta-blockers are equally effective in the improvement of severe HF, but bisoprolol shows favorable effects in patients with AF.
机译:背景:卡维地洛和比索洛尔是治疗心力衰竭(HF)患者的有效药物,但只有少数报道比较了它们的作用。本研究旨在比较它们在重症心衰患者中的作用。方法和结果:回顾性调查了655例连续的HF患者,归类为纽约心脏协会3级或4级。这些患者中,有217位患者在入院后接受了β受体阻滞剂的治疗,分为两组(卡维地洛,n = 110;比索洛尔,n = 107)。在引入β受体阻滞剂之前,两组之间的特征没有发现显着差异。随访18个月后,两组之间的存活率和无心脏事件发生率无显着差异。相反,房颤(AF)患者有几个显着差异(卡维地洛,n = 40;比索洛尔,n = 43)。与卡维地洛组相比,比索洛尔组心率和脑钠肽水平的百分比变化显着改善。此外,比起卡维地洛组,比索洛尔组从房颤到窦性心律除颤的患者更多(48%vs 16%; P = 0.03)。结论:我们的数据表明2种β受体阻滞剂在改善严重HF方面同样有效,但比索洛尔对AF患者显示出有利的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号